These include research studies over a small molecule for multiple myeloma, the development of a Zika vaccine, seasonal influenza vaccine trials and cell therapy studies for chronic lymphocytic leukemia
ICMR inks agreements with industry, academic partners to advance first-in-human phase-1 clinical trials
